MarketPulse

FDA Complete Response Letter

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky

ALDX Stock Collapses 71% After FDA Rejection Exposes Clinical Trial Deficiencies

FDA rejection of Aldeyra's dry eye drug triggers 71% stock crash and securities fraud lawsuit. Investors can apply for lead plaintiff status until May 29, 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Rosen Law Firm

Disc Medicine Stock Plunges 22% After FDA Rejection of Bitopertin Drug

Disc Medicine stock fell 22% after FDA rejected its bitopertin drug application, prompting securities litigation investigations and shareholder claims.
IRONstock declineinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Disc Medicine Stock Plummets 22% After FDA Bitopertin Rejection

Disc Medicine stock drops 22% after FDA rejects bitopertin application. Litigation investigation launched to assess shareholder damages and potential securities violations.
IRONstock declineinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Disc Medicine Stock Plunges 22% After FDA Rejection; Class Action Investigation Underway

Disc Medicine ($IRON) shares tumbled 22% following FDA rejection of its bitopertin program. Law firm investigates potential securities violations and shareholder losses.
IRONNUAINUAIWIMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

Aldeyra Plunges 71% on Failed Trial Disclosure; Securities Lawsuit Deadline Looms

Aldeyra Therapeutics faces federal securities lawsuit alleging inadequate disclosure of failed clinical trial results for reproxalap. Stock crashed 71% after FDA rejection; investor deadline May 29, 2026.
ALDXsecurities class actionstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Corcept Therapeutics Hit With Class Action Suit After FDA Rejection Triggers 50% Stock Plunge

Pomerantz Law Firm files class action lawsuit against $CORT after FDA rejection of relacorilant causes 50.4% stock decline. Investors urged to act by April 21, 2026 deadline.
CORTEOSENKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Aldeyra Therapeutics Faces Securities Fraud Suit Over Hidden Trial Data Inconsistencies

Aldeyra Therapeutics faces securities fraud lawsuit alleging it concealed reproxalap trial data inconsistencies, leading to 70.7% stock collapse after FDA rejection in March 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Aldeyra Therapeutics Hit with Class Action Over Failed Drug; Stock Plummets 70%

Robbins LLP sued Aldeyra Therapeutics over alleged investor misrepresentation regarding failed drug reproxalap. FDA rejected approval; stock fell 70.7%. Lead plaintiff deadline: May 29, 2026.
ALDXclass action lawsuitlead plaintiff deadline